On 10 April 2013, St Jude Medical announced European CE mark approval of its Brio, Libraand LibraXP deep brain stimulation systems for managing the symptoms of intractable primary and secondary dystonia. This approval represents the first regulatory agency approval for the use of deep brain stimulation to manage both primary and secondary dystonia, according to the company.
“Dystonia strikes people of all ages including children and young adults, often leaving them disabled and sometimes wheelchair bound,” said Elena Moro, professor of neurology at the University Hospital Center of Grenoble, France. “For patients who do not respond to medications, deep brain stimulation therapy may alleviate symptoms such as repetitive, twisting movements, allowing them to improve their independence and overall quality of life.”
Deep brain stimulation therapy for dystonia involves the delivery of mild electrical pulses to a specific target in the brain. Stimulation is delivered to one of two regions, the subthalamic nucleus or the globus pallidus interna, areas of the brain involved with controlling movement. Irregular nerve signals responsible for some of the disabling symptoms are stimulated by deep brain stimulation therapy, ultimately helping the patient improve movement, according to St Jude Medical press release.
“This CE mark is the first approval by a regulatory agency for the use of deep brain stimulation therapy to manage the symptoms of both primary and secondary dystonia, broadening the treatment options for patients in Europe whose lives are impacted by this disabling disease,” said Eric S Fain, president of the St Jude Medical Implantable Electronic Systems Division. “This approval represents a significant milestone for St Jude Medical as we continue to develop therapies to treat a broad range of neurological conditions.”